Novo Nordisk reported Q3 results this morning and beat on nearly every line. Revenue rose 6% year over year to DKK 79.195 billion, and adjusted operating profit increased 27% at constant exchange rates. Wegovy pill sales totaled DKK 5.394 billion. The stock jumped about 6% on the news. That reaction, while welcome, barely makes a dent in what has been a painful year for NVO shareholders, and it raises a question that matters more than any single quarter: how long can the world’s dominant obesity drug maker trade at a single-digit price-to-earnings ratio?
The Business
Wegovy is not a product. It is a franchise. By the end of Q3, the Wegovy pill had been launched in the U.S., UAE, UK, and Germany, and launches in four additional countries brought the total to eight markets. Pill sales in the quarter totaled DKK 5.394 billion. Injectable Wegovy came in at DKK 20.407 billion and Ozempic injectable at DKK 29.657 billion.
Adjusted operating profit increased 27% at constant exchange rates, driven by GLP-1 sales growth and a favorable comparison base following DKK 9 billion in transformation costs recognized in Q3 2025. The underlying business is doing what it needs to do. The pill transition is working faster than expected. Wegovy pill revenue reached DKK 5.394 billion. The pill is now large enough to offset weakness in established products.
Why Wall Street Is Paying Attention
Novo raised its full-year guidance this morning. In Q3, the company reported adjusted EPS of DKK 5.79. Reported operating profit was weighed down by DKK 8.7 billion of non-cash impairment charges, but the market focus was on the adjusted beat and the upgraded outlook. The company also updated its 2026 sales growth outlook, reflecting optimism around its GLP-1 product portfolio. A guidance raise on top of a broad beat signals management confidence, not a one-quarter fluke. The Danish weight-loss drug maker is looking to regain momentum following a tumultuous year in which it fell behind rival Eli Lilly. Today’s quarter makes that case meaningfully.
What’s Driving the Opportunity
The valuation gap is the story. NVO is trading at roughly 10x trailing earnings based on widely quoted trailing P/E metrics, well below where it traded during much of the last decade. Industry comparisons vary by data provider, but at least one widely used industry dataset puts the drug manufacturers median forward P/E around 15.2, still above where Novo currently trades. These are not fringe estimates. Multiple valuation frameworks can support the view that expectations embedded in the stock have reset sharply lower even as core GLP-1 demand remains durable.
Novo operates in a tight duopoly with Eli Lilly, and the GLP-1 market is still in early innings globally. The pill format removes the injection barrier that limited addressable patients in prior years. Eight markets in one quarter is not a soft launch.
What Could Go Wrong
Planned U.S. price cuts and intensifying Eli Lilly competition remain key investor concerns. The stock fell nearly 8% in one session in late September after the company’s strategy update failed to reassure investors about the path beyond today’s GLP-1 leaders. Injectable Wegovy sales fell 2% at constant exchange rates this quarter, and GLP-1 diabetes sales declined in the quarter at constant exchange rates as well. If the pill cannibalizes the injectable franchise without growing the overall market, the revenue math changes. Currency moves can also compress reported figures in a way that distorts the underlying picture.
The Bottom Line
Novo Nordisk is the most globally distributed GLP-1 platform in existence, it raised guidance this morning, and it is trading at roughly half the multiple of its own long-run history on common trailing P/E measures. The pill transition cleared its first real test today with Wegovy pill sales of DKK 5.394 billion. Lilly raised its full-year outlook last week on strong Mounjaro and Zepbound demand. Both companies are winning. At a sub-10x trailing earnings multiple, NVO is being priced as if only one of them will.
